Published in Biotech Law Weekly, October 29th, 2004
Transmucosal delivery offers the potential for once-daily dosing of oral drugs and avoids the effects of first pass metabolism.
Demand for transmucosal drug delivery will benefit from several converging market forces. The shifting population demographics in developed societies will drive an increasing demand for palliative treatments associated with an aging patient base....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.